Viatris Posts Q1 Profit Despite 5% Dip In Sales, Reiterates FY22 Guidance Above Consensus

  • Viatris Inc VTRS reported Q1 FY22 sales of $4.18 billion, down 5% Y/Y (-1% on an operational basis), below the consensus of $4.23 billion.
  • Brands performed better than expectations, such as Lipitor, Effexor, and Perforomist.
  • Complex generics and biosimilars grew by 21% Y/Y on an operational basis, driven mainly by the generic Restasis launch in February, partially offset by competition in select complex generics products. 
  • Viatris generated approximately $120 million in new product revenues, primarily driven by the launch of generic Restasis and interchangeable Semglee in the U.S., and is on track to achieve approximately $600 million in new product revenues in 2022.
  • It reported EPS of $0.33, a turnaround from an EPS loss of $(0.86) a year ago.
  • Adjusted earnings increased 1% to $1.13 billion, while adjusted EBITDA declined 3% to $1.59 billion.
  • The adjusted gross margin remained unchanged at 59.5%.
  • The company generated $1.07 billion of free cash flow.
  • Viatris's quarterly dividend of $0.12 per common share is payable on June 16, 2022, to shareholders of record on May 24, 2022.
  • Guidance: Viatris reaffirms FY22 sales of $17 billion - $17.5 billion, compared to the consensus of $17.24 billion.
  • It forecasts adjusted EBITDA of $5.8 billion - $6.2 billion and free cash flow of $2.5 billion - $2.9 billion.
  • Price Action: VTRS shares are up 6.83% at $10.63 during the market session on Monday's last check.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!